From NasdaqomaX.:



Soleno Therapeutics’ stock price received a 10% lift after a Guggenheim analyst raised the price target to $44 per share from $40. The stock closed 2.4% higher on Thursday, outperforming the S&P 500 index. Soleno is a biotech company focusing on the treatment of rare diseases, specifically Prader-Willi Syndrome. Their leading drug candidate, Diazoxide Choline, showed promising results in a clinical trial. However, the company’s net loss in the third quarter disappointed investors. The Motley Fool Stock Advisor analyst team recommended 10 best stocks for investors to buy now, but Soleno Therapeutics was not one of them. Despite the current disappointments, there is potential for significant growth if DCCR receives FDA approval. The Motley Fool Stock Advisor service has a strong track record of outperforming the S&P 500.



Original: Why Soleno Therapeutics Stock Ticked Higher on Thursday